Tag Archives: Brexanolone

A Primer on Brexanolone (Zulresso) for Postpartum Depression

Since the the Food and Drug Administration (FDA) approved brexanolone as an intravenous infusion for the treatment of postpartum depression last week, we have been deluged with questions from patents, providers and the media regarding this new drug.  Sage Therapeutics plans to market the drug under the name ZULRESSO and plans to launch in the… Read More: A Primer on Brexanolone (Zulresso) for Postpartum Depression »

Brexanolone for Postpartum Depression: More Data, But Still Some Questions

In 2015, we first reported on SAGE-547 (SAGE Therapeutics), a new medication for the treatment of severe postpartum depression (PPD).  SAGE-547, now called brexanolone, is an allosteric modulator of GABA-A receptors.  We saw the preliminary results of the Sage Therapeutics Phase 3 Hummingbird Program earlier this year.  Now we have the final set of results… Read More: Brexanolone for Postpartum Depression: More Data, But Still Some Questions »